Rayner announces launch of RayOne Galaxy spiral IOL

News
Article

The IOL, designed with artificial intelligence, will launch at this year's ESCRS Congress in Barcelona, Spain

The RayOne Galaxy spiral IOL in a package. Image courtesy of Rayner.

Clinical investigators are expected to present their findings on the RayOne Galaxy at this year's ESCRS meeting in Barcelona, Spain. Image courtesy of Rayner.

On Monday, ophthalmic surgery manufacturer Rayner announced a new addition to its intraocular lens (IOL) offering, designed using a proprietary artificial intelligence (AI) engine. In a press release, Rayner, based in Worthing, UK, shared details about the RayOne Galaxy and Galaxy Toric, which will launch at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) Congress in Barcelona, Spain.1 The lens will come fully preloaded across the RayOne product line’s power range and will be immediately available in toric powers.

According to Rayner, the RayOne Galaxy has a unique spiral lens, formulated to deliver a continuous full range of vision and minimise dysphotopsia. The company developed the RayOne Galaxy in conjunction with João Marcelo Lyra, MD, PHD, who is affiliated with Universidade Estadual de Ciências da Saúde de Alagoas (UNCISAL), Maceio, Alagoas, Brazil. Additionally, the IOL was developed using an AI “trained on patient outcomes,” resulting in a non-diffractive optic with 0% light loss. The press release from Rayner noted the lens is the “world’s first spiral IOL designed with artificial intelligence.”

Clinical investigations with RayOne Galaxy began earlier in 2024 in Brazil and throughout Europe.1 Eight leading surgeons began using the RayOne Galaxy in their clinical practices, and a number of those surgeons will present initial findings at a Rayner symposium during the ESCRS Congress. Mr Allon Barsam, Consultant Ophthalmic Surgeon and Director at OCL Vision in London, United Kingdom, said the first patients received the RayOne Galaxy lens at OCL Vision in July. “Their feedback so far has been overwhelmingly positive, with patients reading without glasses and thrilled with their quality of vision,” Mr Barsam reported in the press release.

Tim Clover, CEO of Rayner, gave a statement about the AI-supported development of the lens. “We all read about the life changing potential of AI, but this is a real-world example of technology impacting the outcomes of patients,” he said. “RayOne Galaxy represents a next generation technology in intraocular lenses to enable patients to see without spectacles.”

Reference

1. Rayner announces launch of world’s first spiral IOL designed with AI. Press release. Rayner Group. Published 26 August, 2024.
Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.